Physician profile
Mark D Cipolle
NPI 1609883289
$1,127.50
in general payments reported to CMS, 2019-2025
12 companies · $291 in 2025
The $291 reported for 2025 was more than what a typical Surgical Critical Care provider received nationally (typical 2025 total: $234).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $268 · 2021: $56.75 · 2022: $14.23 · 2023: $497 · 2025: $291.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $789.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $788.67 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Haemonetics Corporation | $244.33 | 2023-2025 | Teg6s Hemostasis System |
| Baxter Healthcare | $242.03 | 2019-2023 | Perclot |
| Abbott Laboratories | $203.43 | 2023 | Proclaim |
| Kerecis Limited | $147.63 | 2025 | Kerecis Surgiclose, Kerecis Graftguide |
| Csl Behring | $145.42 | 2019 | |
| Avanos Medical | $39.11 | 2021 | |
| Acera Surgical, INC. | $29.48 | 2025 | Restrata Wound Matrix |
| Kci USA, INC. | $22.43 | 2019 | |
| Braintree Laboratories, INC. | $21.77 | 2023 | Sutab |
| Integra Lifesciences Corporation | $17.64 | 2021 | |
| Medtronic, INC. | $14.23 | 2022 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Cipolle listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.